This Friday, the World Health Organization (WHO) gave the green light to two new drugs against Covid-19: Baricitinib and Sotrovimab, reported Prensa Latina.
Baricitinib is a Janus kinase inhibitor drug and is used to reduce inflammation and treat rheumatoid arthritis.
According to the health entity, its use is especially recommended in patients with covid-19 in serious or critical condition, in combination with corticosteroids, a variety of hormones used to cure the first of these diseases.
Regarding this drug, experts point out that it improves survival capacity and reduces the need for assisted breathing, without observing an increase in side effects.
In addition, the WHO statement indicates, it has similar effects to those of other arthritis drugs called interleukin 6 inhibitors, so when both are available, specialists suggest choosing one based on cost, availability and availability. physician's preference.
On the other hand, the text details, the use of both drugs at the same time is not recommended and they advise against joining two Janus kinase inhibitors (Ruxolitinib and Tofacitinib) in patients with covid-19 in serious or critical condition, since evidence of poor reliability in clinical trials did not show any benefit and suggest a possible increase in serious side effects with tofacitinib.
The Sotrovimab recommendation was formulated for patients with SARS-CoV-2 coronavirus that is not severe, but only for those with a higher risk of hospitalization.
Both authorizations were based on tests carried out during seven clinical trials in which more than four thousand patients with mild, severe and critical covid-19 infection participated and after the approval of several international experts working in a Guideline Development Group. of the health agency, the results of which were published in the British Medical Journal.
With these approvals, the WHO adds new guidance to previous COVID-19 treatments on the use of interleukin-6 inhibitors and systemic corticosteroids for patients in severe or critical condition.
In addition, conditional recommendations on the use of Casirivimab-imdevimab in certain infected patients and the rejection of the use of convalescent plasma, Ivermectin and Hydroxychloroquine were disclosed.